The clinical significance of anti-CCP antibodies in Korean JRA patients
© Kim and Rhim; licensee BioMed Central Ltd. 2014
Published: 17 September 2014
To determine the clinical significance of anti-CCP (anti-citrullinated cyclic peptide) in Korean patients with JRA. Rheumatoid Factor (RF) is a non-specific serologic test in juvenile rheumatoid arthritis (JRA) but the anti-perinuclear autoantibodies are found in adult rheumatoid arthritis (RA) recently. One of these autoantibodies can detect epitopes called citrulline. The authors want to know that these autoantibodies can be applied in Korean JRA.
The serum samples were obtained from 142 patients with arthralgia. The mean ages are 8.98 years old. The case group were 83 patients with JRA and the other control group were 59 patients with arthralgia who are not JRA.
The ant-CCP antibodies were assessed by an enzyme linked immunosorbent assay (ELISA) : INOVA Quant Lit CCP3 IgG ELISA test.
The authors compared the anti-CCP values with each JRA subtypes. Each subtypes are systemic JRA (29 cases), pauci JRA (31 cases) and poly JRA (23 case). The p-values are 1.0, 0.272 and <0.01 respectively. We are also compared the anti-CCP values with RF-positive and RF-negative in poly JRA. The p-values are <0.01 and <0.01 both.
The authors compared the JRA group with the control group. The p-value revealed <0.01 significantly. We also compared each subtype of JRA with control group. Only the poly JRA group is significantly differences with control group (p<0.01). We concluded that the test for anti-CCP in poly JRA patients are significantly benefit in the clinical field.
Disclosure of interest
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.